Category: eHealth

The World Health Organization (WHO) together with the World Organisation for Animal Health (WOAH), United Nations Environment Programme (UNEP), and the Food and Agriculture Organization of the United Nations (FAO) made up the Quadripartite organizations. This partnership of the four organizations has established the Quadripartite Technical Group on Integrated Surveillance on antimicrobial use and resistance, which will advise the Quadripartite Organizations and the Global Leaders Group on Antimicrobial Resistance (AMR) on needs, scope and form of integrated surveillance to support capacity building of countries on surveillance of antimicrobial use (AMU) and resistance.

If you are interested in learning more about the role of the Technical Group on Integrated Surveillance on Antimicrobial use and resistance and its areas of advice, please use these links:

To read the article, visit: https://www.who.int/news/item/26-01-2023-the-quadripartite-organizations-established-the-technical-group-on-integrated-surveillance-on-antimicrobial-use-and-resistance

To read more information, visit:

https://cdn.who.int/media/docs/default-source/antimicrobial-resistance/qtg-ais/qtg-amr-amu-integrated-surveillance-tors.pdf?sfvrsn=43f45ec4_3

The establishment of the Technical Advisory Group on Local Production and Technology Transfer (TAG-LPTT) of health products has been finalized by the Local Production and Assistance Unit (LPA) and Access to Medicines and Health Products (MHP) Division of WHO. It has been established with the aim to provide strategic and technical advice to WHO in the field of promoting and strengthening sustainable local production and technology transfer to improve access to quality, safe and effective health products. The establishment of the TAG-LPTT to address current and future global challenges and trends in local production and technology transfer represents the execution of one World Local Production Forum’s recommendations.

More about the role, structure, and beginnings of the TAG-LPTT you may find in the links below.

To read the article, visit:

https://www.who.int/news/item/21-02-2023-multidisciplinary-technical-advisory-group-established-to-advice-who-on-local-production-and-technology-transfer-of-health-products

To read more information on the Local Production and Assistance Unit (LPA), visit: https://www.who.int/teams/regulation-prequalification/lpa#:~:text=The%20Local%20Production%20%26%20Assistance%20

Salt or the so-called table salt (sodium chloride) is the main source of sodium, although it also could be found in other condiments, such as sodium glutamate. Sodium is an essential nutrient, which increases the risk of heart disease, stroke and premature death when eaten in excess, which are strong arguments to reduce the overall salt consumption in the world. Moreover, implementing highly cost-effective sodium reduction policies could save an estimated 7 million lives globally by 2030.

Why is salt consumption in the world still at high levels? And which countries have comprehensive packages of recommended policies to reduce sodium intake? What tools and measures are being taken to reduce sodium consumption? These and more questions will be answered in the article published by the World Health Organisation.

To read the article, visit:

https://www.who.int/news/item/09-03-2023-massive-efforts-needed-to-reduce-salt-intake-and-protect-lives

To read the report, visit: https://www.who.int/publications/i/item/9789240069985

Europe has gone from thinking music could stop plagues 400 years ago to realising it can help prevent cardiovascular disease today.

More than one in five people aged 15 years and over in the EU have reported having high blood pressure, which can lead to failure in the heart, kidneys or brain. Lowering blood pressure even slightly can reduce the risks of cardiovascular disease.

From the Science and Technology of Music and Sound Laboratory in Paris to King’s College London, Professor Elaine Chew is developing an app for smartphones to boost heart health as part of an EU-funded project called HEART.FM.

‘We’re creating an app that will monitor people’s response as they listen to music and then tailor that music to benefit them,’

More Info: https://ec.europa.eu/research-and-innovation/en/horizon-magazine/high-blood-pressure-heart-app-prescribes-musical-therapy

DMEA – Europe`s Leading Event for Digital Health to take place from 25 to 27 April in the Berlin exhibition halls

The DMEA is one of Europe’s most important events for digital health. Once a year, experts from the digital health industry meet for three days in Berlin. In addition to a comprehensive market overview, the DMEA offers all players a wide range of opportunities for intensive exchange, targeted networking and effective customer acquisition.

From 25 to 27 April 2023 on the Berlin Exhibition Grounds the focus will be on the digital transformation of the healthcare system. On the stages at DMEA and at the Hub and Box, topics will get to the core of digital health, ranging from the electronic patient file, telemedicine and interoperability to the digitalisation strategy for the healthcare system and nursing sector. 

More info: https://www.dmea.de/en/about/dmea/

A biopharmaceutical therapeutics company to Incorporate Wearable and Invisible Contactless Digital Health Technologies in Parkinson’s Disease Clinical Trial

A clinical stage biopharmaceutical company announced a collaboration with Innovation Lab companies that focused on using wearable and invisible contactless digital health technology to improve monitoring and data collection for Parkinson’s disease clinical trials.

Currently, monitoring and data collection in Parkinson’s disease clinical trials combine subjective patient-reporting tools such as diaries and questionnaires with periodic neurological and mobility assessments in a clinical setting that only capture a specific moment in time. Unfortunately, this approach fails to give a full, real-time picture of disease progression and the impact of a patient’s daily experience with Parkinson’s symptoms.

The use of these digital technologies is expected to collect an unbiased, objective, and continuous measure of disease impact on function that will help develop more effective therapies.

More info: https://www.digitalhealthnews.eu/industry/6918-bluerock-therapeutics-to-incorporate-wearable-and-invisible-contactless-digital-health-technologies-from-rune-labs-and-emerald-innovations-in-parkinson-s-disease-clinical-trial